To make medicine investment, we must have a different model

As the medical industry is now in hot weather and the pressure of competition is relatively large, to do investment in medicine, we must know that the market is always dynamic, and that no market is immutable. With the expansion of sales scale, the price of both companies and agents is also increasing. The bigger. In order to effectively manage the agents, the company constantly adjusts the agency policies. The fine management of pharmaceutical investment agents is an objective requirement for the sustainable development of pharmaceutical companies. The investment agency model is constantly evolving and innovating--joint development. Enterprises need to have a different model for doing drug attraction.

First, the lack of a good drug investment model for drug investment enterprises is not conducive to the establishment of a brand image and long-term development of enterprises, and they cannot exercise their own sales force. Rely on agents for a long time, unable to effectively break sales bottlenecks, unable to withstand market risks and so on. With the passage of time, the problem of the drug investment agency model itself has also increased, manufacturers and agents have a stomach of complaints and frustration. Drugs investment promotion believes that most of the agents value short-term interests. There is no good model for drug investment. It is difficult for agents to cooperate with the long-term development of enterprises, and it is difficult to truly become a long-term strategic partner.

Second, with the increasing costs and risks, agents are obviously concerned that companies will withdraw from the market without investing or failing. Faced with this situation, pharmaceutical investment companies can attract agents only if they have good drug investment models. Retain the agents and cooperate for a long time. For the drug investment model, good products and unique positioning and creativity are the key to attracting powerful, terminal pharmaceutical investment, and then bigger products. Product positioning can be refined from both product and brand levels.

Thirdly, brand-building is a key factor that affects whether or not an enterprise can grow and develop. The supply capacity of the pharmaceutical market is far greater than the actual demand. Faced with this situation, the pharmaceutical investment enterprise will be able to do a good job at three points, and then take a lot of detours, and make the drug investment road more and more widely. Changes in these matters will directly affect the sales situation of drug investment enterprises, and the specific circumstances of customers will directly affect the company's progress in market sales in a particular region. To let the market go its own way, it is better to study the characteristics of the drug investment market and implement personalized development.